Twist Bioscience Logo
US90184D1000
A2N7L2
TWST

Twist Bioscience

Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti è 131,97 € (+27,78%). La mediana è 124,77 € (+20,81%).

Acquista
  11
Mantieni
  2
Vendi
  2

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • Twist Bioscience supplies DNA and protein production for AI-powered drug discovery

    Twist Bioscience manufactures synthetic DNA on its own silicon platform and offers protein expression as well as antibody and characterization services. This allows the company to translate AI-designed DNA and protein sequences into real, testable biology and places it at the interface that is crucial for accelerated drug development. Analysts see significant growth potential in AI-assisted research. » Altro su finanzen.net


  • Twist Bioscience benefits from Lilly deal and raises outlook after revenue record

    Twist Bioscience was engaged as the preferred data provider for Eli Lilly’s TuneLab platform, strengthening its role in AI-powered drug discovery. Q3 revenue rose 23% to $118.38 million, and the outlook for 2026 was noticeably raised. Despite slightly missing the EPS target, the improved gross margin of 52.8% and the AI boom drew increased investor interest. » Altro su finanzen.net


  • Twist Bioscience partners with Lilly TuneLab to provide antibody characterization data

    Twist Bioscience will supply antibody characterization services and high-throughput wet‑lab data to Lilly's TuneLab and its AbLab developability model, allowing TuneLab users to order Twist's protocols and data to support AI-enabled antibody discovery. The collaboration positions Twist as a data-generation and antibody‑characterization provider within the AI-driven drug discovery ecosystem and could create incremental service revenue if TuneLab adoption rises. The agreement contains no disclosed minimum purchase commitments, milestones, or commercialization economics, so near‑term revenue impact is uncertain and depends on user demand for Twist's services. » Altro su finance.yahoo.com


  • Parnassus adds Twist Bioscience to growth fund, cites AI drug discovery and silicon DNA synthesis

    Parnassus Growth Equity Fund added Twist Bioscience in Q2 2026, highlighting its proprietary silicon-based DNA synthesis platform and exposure to AI-supported drug discovery and next-generation sequencing. The fund said the platform offers higher throughput and lower costs, creating a durable competitive advantage as Twist pursues market share. Twist closed at $138.10 on Sept. 15, with a 52-week gain of 443.64% and a market capitalization of $9.09 billion. » Altro su finance.yahoo.com


  • ARK Invest sells Twist Bioscience stake and increases Intellia position

    ARK Invest sold 46,015 shares of Twist Bioscience via the ARKK ETF, worth around $5.84 million, and also reduced holdings in 10X Genomics, Bullish, Tempus AI, GeneDx and Alphabet. At the same time, ARK bought 114,989 shares of Intellia Therapeutics for about $1.37 million, continuing the recent build-up of its Intellia position. The trades point to a strategic portfolio reshuffle, reducing some biotech and technology names while increasing other positions. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Twist Bioscience ha registrato ricavi pari a 111,81 Mln € e un utile netto di -18,21 Mln €
(EUR) settembre 2026
YoY
Ricavi 111,81 Mln 32,52%
Utile lordo 59,37 Mln 37,06%
Utile netto -18,21 Mln 21,27%
EBITDA -37,86 Mln 112,81%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
6,3 Mld €
Numero di azioni
65,83 Mln
Massimo/minimo a 52 settimane
200,09 € - 22,23 €
Dividendi No
Beta
2,22
Rapporto P/E
-50,50
Rapporto PEG
0,76
Rapporto P/B
7,41
Rapporto P/S
15,05

Profilo aziendale

Twist Bioscience Corporation, un'azienda di biologia sintetica, produce e commercializza prodotti basati sul DNA sintetico. La piattaforma di sintesi del DNA dell'azienda consente la produzione di DNA sintetico scrivendo il DNA su un chip di silicio. Offre prodotti basati sul DNA sintetico, tra cui geni sintetici, strumenti per la preparazione dei campioni, librerie di anticorpi per la scoperta e lo sviluppo di farmaci e il DNA come mezzo di archiviazione di dati digitali. L'azienda ha accordi di collaborazione con Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; e Centogene N.V per sviluppare strumenti di sequenziamento avanzati. Inoltre, ha una collaborazione di ricerca con Boehringer Ingelheim International GmbH per utilizzare librerie di anticorpi proprietarie al fine di scoprire anticorpi terapeutici contro più bersagli. Twist Bioscience Corporation è stata costituita nel 2013 e ha sede a South San Francisco, California.

Nome
Twist Bioscience
CEO
Emily Marine Leproust
Sede centrale South San Francisco, ca
Stati Uniti
Sito web
Settore
Sanità
Industria
Biotecnologia
Quotazione in borsa
31/10/2018
Dipendenti 979

Simboli di borsa

Borsa Simbolo
NASDAQ
TWST
Frankfurt
0ME.F
Düsseldorf
0ME.DU
München
0ME.MU
🍪

Parqet  usa i cookie. Scopri di più